Approval BlogMedical CommunicationsOncology Updates Rucaparib for Maintenance Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Blinatumomab for Patients with MRD-positive B-cell Precursor ALL By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Nilotinib Receives FDA-approval to Treat Pediatric Patients with Chronic Phase CML By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Medical CommunicationsOncology Updates Adcetris is Approved for the Frontline Treatment of stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy By Zachary Moore | Medical Communications, Oncology Updates
Medical CommunicationsOncology Updates Abemaciclib, Another Option for Frontline Treatment of HR-positive Breast Cancer By Zachary Moore | Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Apalutamide, a New Treatment for Nonmetastatic Castration Resistant Prostate Cancer By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Expanded Approval for ZYTIGA® for the Treatment of Castration-sensitive Prostate Cancer By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Lutathera®, a New Treatment Option for Patients with Neuroendocrine Tumors By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Olaparib, the First PARP Inhibitor to Gain FDA Approval to Treat BRCA-mutant Breast Cancer By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Afatinib receives extended approval for frontline treatment of Patients with Non-resistant EGFR Mutation-positive NSCLC By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
